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Introduction
The extensive genetic diversity of the human immunodeficiency virus (HIV) poses a formidable challenge to the development of an efficacious preventive HIV vaccine (HVTN, 2006 ). An HIV vaccine may prevent infections with viruses genetically similar to a virus represented in the vaccine, but fail against genetically dissimilar viruses.
Data on the amino acid sequences of the viruses that infect participants in preventive HIV vaccine efficacy trials can be used to assess how the efficacy of the candidate vaccine depends on genetic mismatching of exposing viruses. "Sieve analysis" methods have been developed for this purpose, which are based on comparing the genetic distances (to the vaccine sequence) of the sequences of infected vaccine recipients to the genetic distances of the sequences of infected placebo recipients (Gilbert, Self, and Ashby, 1998) . Previously developed sieve analysis methods considered "low dimensional" cases in which viruses are classified exhaustively by a small number of K genotypes/phenotypes, or are ordered by K scalar summary measures of distance.
However, there are many thousands of distinct HIV genotypes as defined by amino acid sequence. Consequently, the problem of identifying sequence positions that distinguish the two sets of infecting viruses is a high dimensional data problem, in which the number of variables (sequence positions) exceeds the number of observations (infected subjects). In a typical efficacy trial, 100-400 subjects are infected and 500-3300 sequence positions are studied.
The data set available from an efficacy trial that we consider is the aligned HIV amino acid sequences sampled from infected vaccine and placebo recipients, with one sequence per subject. We develop techniques for "genome scanning," whereby at each position, the amino acids in the two aligned sequence sets are compared to the amino acid at the corresponding position in the reference sequence, and the goal is to identify "signature positions" (see Figure 1) . A signature position is a position at which vaccinee sequences exhibit significantly greater divergence from the reference amino acid than placebo sequences. Identifying a signature position may suggest that amino acid changes in that position were required in order for HIV to elude the vaccine-induced immune response and hence establish infection. For example, certain N-linked glycosylation positions in the glycoprotein 120 (gp120) region of HIV (gp120 is composed of a protein and a carbohydrate and is exposed on the surface of the HIV envelope), appear critically important for HIV to evade neutralization (Wei et al., 2003) , and the vaccine may fail to protect against viruses with certain mutant amino acids in these positions.
Finding a signature position could imply the necessity to insert multiple different HIV strains into the vaccine, with amino acid sequences that match contemporary circulating HIV strains, in order for the vaccine to protect broadly. Therefore the results of genome scanning analyses can guide the design of new vaccines.
A "signature position" may alternatively be defined as a position at which the amino acid frequency distributions differ among the two sequence sets, irrespective of any reference amino acid. We develop methodology for detecting both types of signature positions. Henceforth we refer to signature positions involving (not involving) a reference amino acid as type A (type B) signatures.
The data set we analyze derives from the first HIV vaccine efficacy trial (Flynn et al., 2005) . Healthy HIV uninfected volunteers were randomized to receive vaccine (N v = 3598) or placebo (N p = 1805) and were tested for HIV infection every 6 months for 36 months. The vaccine was a recombinant envelope gp120 subunit vaccine, designed to prevent acquisition of HIV by inducing antibodies that could bind to neutralizing epitopes on HIV gp120 and destroy the virus before it infects host cells. The vaccine did not prevent HIV infection, with a similar rate of infection in the vaccine (241/3598 = 6.7%) and placebo (127/1805 = 7.0%) groups. For 336 of the 368 infected participants three HIV isolates were sampled at the time of HIV infection detection, and the amino acid sequence of gp120 was determined by direct translation of the DNA sequence for each isolate. Sequences from the same individual were highly similar, and we considered one randomly selected sequence from each subject. The 336 gp120 sequences were aligned together with the two gp120 sequences that were represented in the vaccine construct, named MN and GNE8. The alignment was constructed using ClustalX v.1.81 (Thompson et al., 1997) and manually edited. Since GNE8 was sampled more recently and was closer genetically to the infecting sequences, it was used as the reference sequence in all analyses. There are n 1 = 217 vaccine group sequences and n 2 = 119 placebo group sequences, each of length p = 581.
Consideration of one of the most commonly used methods for studying HIV signature positions, VESPA (Korber and Myers, 1992 ; http://hiv-web.lanl.gov/content/hivdb/mainpage.html), demonstrates the need for new methodology. VESPA is purely descriptive-it evaluates potential type B signatures by comparing the frequency of the most common amino acid at positions between two sequence sets, without considering the particular amino acids involved, and without using a probabilistic framework to control error rates. Our approach to the scanning analysis divides into three parts:
1. For each position, construct a two-sample test statistic that compares amino acid divergences (type A) or frequencies (type B) between the two sequence sets; 2. Approximate the null distribution of the test statistics across the set of studied amino acid positions, and obtain position-specific p-values; 3. Determine the set of signature positions as those with p-value less than a cut-off p cut , estimated to control a false positive error rate at a pre-specified level. For 1., various statistics for evaluating amino acid sequence differences have recently been proposed, based on standardized Euclidean distance and Kullback-Leibler discrepency (Wu, Hsieh, and Li, 2001) , and Mahalanobis distance (Kowalski, Pagano, and DeGruttola, 2002) . These metrics/discrepencies were developed in different contexts than genome scanning analysis, so their relative utility for our application is unknown. Accordingly we develop and compare test statistics based on all three of these approaches, and for problem A, generalize the Euclidean-type statistics to incorporate weight functions that can make amino acid distances more immunologically relevant and thus potentially more predictive of vaccine efficacy.
For 2., we consider two approaches to approximating the null distributions. The first is a permutation procedure that only uses information at individual positions.
The second approach, following Pan (2003) , pools information across all positions and estimates the null distributions of the test statistics directly and nonparametrically. Efron (2004) also pointed out that a large number of tests presents an opportunity to estimate the null distribution directly as an approach to coping with high dimensional data. We apply both approaches to obtain unadjusted p-values for each of the positions. 
Genome Scanning Methods for Identifying Signature Positions

Preliminaries
The data available for genome scanning analysis are n 1 + n 2 aligned amino acid sequences, one from each infected trial participant (n 1 vaccine arm; n 2 placebo arm), all of which are p amino acids long. For problem A the alignment also includes the reference sequence, which is the HIV sequence represented in the vaccine construct. 
The biological significance of a difference in two amino acids at a position depends on the particular amino acids being compared (e. 
Two-sample Test Statistics for Problem B (No Reference Sequence)
For each position i, test statistics are developed to evaluate Our first three proposed test statistics are based on summing weighted differences 
Heuristically these three statistics incorporate a hierarchy of degrees of regularization to dampen noise due to variance-covariance estimation: the first statistic employs full regularization (no variance estimation), the third statistic employs no regularization (estimate the entire variance-covariance matrix), and the second statistic employs intermediate regularization (estimate the variances but set all covariances to zero). For HIV sequence data sets it is unknown which test performs best, and accordingly our simulations are designed to address this question.
In addition, we consider a test statistic based on Kullback-Leibler discrepency,
which is approximately an expected weighted log likelihood ratio comparing p 1 (i) and p 2 (i). The Kullback-Leibler discrepency has been widely studied and has well-known optimality properties closely related to those of likelihood ratio tests (c.f., Eguchi and Copas, 2002) , which raises the conjecture that it will provide relatively high power.
For problem B our Euclidian-type statistics are defined by
where
The third statistic is given by
where 
is the Mahalanobis statistic that has been used extensively in many applications, although more commonly for quantitative data, not multinomial data (cf., Rao and Chakraborty, 1991) .
The fourth statistic, based on Kullback-Leibler discrepency, is relatively easy to compute. For position i, let
Note that the standard Kullback-Leibler discrepency for comparing p 1 (i) and p 2 (i) is 
Two-sample Test Statistics for Problem A (With a Reference Sequence)
To evaluate a type A signature at position i, we develop tests for
, which assesses equal frequencies of the reference amino acid at position i in the two sequence sets. We base tests of
Section 2.1) between groups k = 1 and 2, with diag(M) = 0. These averages can be 
Judging Statistical Significance
Permutation-based Unadjusted p-values (Marginal-No Pooling)
To Specifically, B perm data sets, each of n = n 1 + n 2 sequences, are generated by independently permuting the group membership labels of the whole sequences. The p-value for position i is calculated as the fraction of the test statistics computed using the B perm permuted data sets that equal or exceed the value of the original test statistic.
Nonparametric Estimated Null Distribution-based Unadjusted p-values (Pooling)
In the second ( is to generate hypotheses about positions that warrant further biological examination, equal weights w 1 (i) = 1 may be recommended, because they prevent subjective biases from influencing the results, and they may be agreed upon broadly among investigators.
For these reasons equal weights are used in the Examples.
To develop the pooling approach, we follow Pan's (2003) clever idea for how to directly nonparametrically estimate the null distribution of hundreds of t-statistics.
Assume that under all H 0 (i)'s, the test statistics of interest Z(i) have the same distribution for i = 1, · · · , p. For each group of sequences separately, randomly permute the sequences into two (almost) equally-sized pieces, labeled sets J k1 , J k2 , k = 1, 2. Define n k2 = n k1 if n k = 2n k1 and n k2 = n k1 + 1 otherwise, k = 1, 2. To evaluate type B signatures, the test statistic Z B E1 (i) of (1) is modified (slightly) to Z Bsplit E1 
Because the numerator of z
Bsplit E1
(i) is the sum of within-sample differences, its mean is zero, and z
(i) can be expected to approximate the null distribution of Z Bsplit E1
(i).
Split statistics Z
Bsplit E2
(i) and z
(i) are formed in the same way, with v 1 (i, a) 2 + v 2 (i, a) 2 added to the denominator of the summand of each statistic, where 
The null distribution of Z Asplit 1 (i) can be approximated by Note that the position weights w 1 (i) affect the p-values because the pooling method is used; weights placed in front of the non-split statistics described in Section 2 would not affect the permutation-based p-values, because they are computed marginally.
We also studied modified versions of the statistics Z (i) that incorporate a small positive constant in the denominator to stabilize the statistic (see Web Appendix A). In simulations these tests had lower power than the tests described above, and therefore are not considered further.
Permutation-Based Control of the Per Comparison Error Rate
We use a permutation-based method that requires no distributional assumptions to estimate the number of false positive rejections V at some pre-fixed number. This 
Screening Out Highly Conserved Positions
There is little or no power to detect signatures at positions with very limited amino acid variability. Therefore highly conserved positions are pre-screened out, based on Tarone's (1990) technique for improving power of the Bonferroni correction for discrete data. Tarone's (1990) 
Simulation Study
Design of the Simulation Study
The simulation study is designed based on data from the first HIV vaccine efficacy trial (Flynn et al., 2005) Web Table 1 ). Each nondiagonal entry of the PAM matrix corresponds to two different amino acids, and equals the estimated probability that either of the amino acids mutates into the other one, given a specified probability of any mutation at all. The estimated probabilities of amino acid interchange were computed based on thousands of observed mutations in HIV sequences (see Web Appendix B). We used the PAM−25 matrix, which specifies a 25% chance that the amino acid at position i in a vaccine recipients' sequence will be mutated. Independently for each alternative hypothesis position and each vaccine group sequence, the amino acid was mutated to one of the 19 other amino acids according to the probabilities in the PAM-25 matrix. Step (1) of the algorithm described in Section 3.3 B null = 1 data set is generated under the complete null hypothesis. The PCER, the false positive rate (FPR, the percentage of true null positions rejected), and the true positive rate (TPR, the percentage of true alternative hypotheses rejected) were estimated by averaging over 250 simulated vaccine trials. The performance of the tests can be compared by plotting the estimated TPRs versus FPRs. We also evaluated the PCER because this error rate can be controlled at a fixed level in applications, whereas precise control of the FPR is difficult to achieve.
Simulation Results
For the type B tests, Figures 2-4 show the estimated TPRs versus FPRs, for the scenarios where 1%, 10%, and 25% of the alternative hypotheses are true, respectively.
We make several observations. First, the Kullback-Leibler (Z The four tests for type A signatures were evaluated using the same simulated data sets. The estimated PCERs are close to their pre-specified values (results not shown).
In addition the tests have comparable TPRs, although the split tests sometimes outperform or underperform the non-split tests (Web Figure 1) . The comparable powers may be explained by the fact that the type A tests are all variants of t-statistics.
Examples
We now consider the evaluation of type A signature positions for the data from the efficacy trial described in the introduction. The matrix M was taken as J − I, or as the reciprocal of the HIV-specific PAM−250 matrix of Nickle et al. (2005) , modified to have zeros on the diagonal and a vector of zeros added to the 21st row and 21st
column. Because the previously available amino acid substitution matrices were built using organisms other than HIV, this PAM may yield more accurate rates of HIV amino acid interchanges. Taking the reciprocal upweights rare amino mismatches, which may have greater biological significance.
The tests were performed using B perm = 10, 000 or B perm split = 1000 permutations and N null = 1 null data set generated in Step (1) of the algorithm described in Section 3.3. Tarone's (1990) 
Discussion
For 
